Βones, stones and androgen deprivation therapy

Hormones (Athens). 2015 Oct-Dec;14(4):668-9. doi: 10.14310/horm.2002.1628.

Authors

Miguel Ángel Arrabal-Polo¹, María Del Carmen Cano-García¹, Miguel Arrabal-Martín²

Affiliations

¹ Urology Department, La Inmaculada Hospital, Huércal-Overa, Almería, Spain.
² Urology Department, University Hospital of Granada, Institute IBS Granada, Granada; Spain.

PMID: 26732168
DOI: 10.14310/horm.2002.1628

No abstract available

MeSH terms

Androgen Antagonists / adverse effects*
Antineoplastic Agents, Hormonal / adverse effects*
Bone Density / drug effects*
Bone Density Conservation Agents / adverse effects
Bone Diseases, Metabolic / chemically induced*
Bone Diseases, Metabolic / diagnosis
Bone Diseases, Metabolic / physiopathology
Bone Diseases, Metabolic / prevention & control
Bone and Bones / drug effects*
Bone and Bones / physiopathology
Humans
Nephrolithiasis / complications*
Nephrolithiasis / diagnosis
Nephrolithiasis / physiopathology
Recurrence
Risk Factors

Substances

Androgen Antagonists
Antineoplastic Agents, Hormonal
Bone Density Conservation Agents